The Europe overactive bladder treatment market is expected to grow from US$ 1,111.05 million in 2022 to US$ 1,318.55 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2022 to 2028.
The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.
Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth
Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4-6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.Europe Overactive Bladder Treatment Market Overview
The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament’s data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.Europe Overactive Bladder Treatment Market Segmentation
The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.
- Based on pharmacotherapy, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022. Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022. Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022. AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Overactive Bladder Treatment Market- By Pharmacotherapy
1.3.2 Europe Overactive Bladder Treatment Market- By Disease Type
1.3.3 Europe Overactive Bladder Treatment Market - By Country
2. Europe Overactive Bladder Treatment Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Overactive Bladder Treatment Market - Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert Opinion
5. Europe Overactive Bladder Treatment Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Urinary Incontinence
5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis
6. Europe Overactive Bladder Treatment Market - Europe Analysis
6.1 Europe Overactive Bladder Treatment Market Revenue Forecast and Analysis
7. Europe Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy
7.1 Overview
7.2 Europe Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
7.3.1 Overview
7.3.2 Mirabegron: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
7.4.1 Overview
7.4.2 Botox: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
7.5.1 Overview
7.5.2 Neurostimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.3 Transcutaneous Sacral Nerve Stimulation
7.5.3.1 Overview
7.5.3.2 Transcutaneous Sacral Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.4 Transcutaneous Tibial Nerve Stimulation
7.5.4.1 Overview
7.5.4.2 Transcutaneous Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
7.5.5.1 Overview
7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.6 Others
7.5.6.1 Overview
7.5.6.2 Others: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
7.6.1 Overview
7.6.2 Anticholinergics: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.3 Solifenacin
7.6.3.1 Overview
7.6.3.2 Solifenacin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.4 Oxybutynin
7.6.4.1 Overview
7.6.4.2 Oxybutynin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.5 Fesoterodine
7.6.5.1 Overview
7.6.5.2 Fesoterodine: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.6 Darifenacin
7.6.6.1 Overview
7.6.6.2 Darifenacin: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.7 Tolterodine
7.6.7.1 Overview
7.6.7.2 Tolterodine: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.8 Trospium
7.6.8.1 Overview
7.6.8.2 Trospium: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.9 Other Anticholinergics
7.6.9.1 Overview
7.6.9.2 Other Anticholinergics: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
7.7.1 Overview
7.7.2 Intravesical Instillation: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8. Europe Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type
8.1 Overview
8.2 Europe Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
8.3.1 Overview
8.3.2 Idiopathic: Europe Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
8.4.1 Overview
8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis
9.1 Overview
9.1.2 Europe: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
9.1.2.1 UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.1 UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.2 UK: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.2.1 UK: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.2.2 UK: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.3 UK: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2 Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.1 Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.2 Germany: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.2.1 Germany: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.2.2 Germany: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.3 Germany: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3 France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.1 France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.2 France: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.2.1 France: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.2.2 France: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.3 France: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
9.1.2.4 Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.4.1 Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.4.2 Italy: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.4.2.1 Italy: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.4.2.2 Italy: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
9.1.2.4.3 Italy: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
9.1.2.5 Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.5.1 Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.5.2 Spain: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.5.2.1 Spain: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.5.2.2 Spain: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
9.1.2.5.3 Spain: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
9.1.2.6 Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.6.1 Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
9.1.2.6.2 Rest of Europe: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
9.1.2.6.2.1 Rest of Europe: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
9.1.2.6.2.2 Rest of Europe: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
9.1.2.6.3 Rest of Europe: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
10. Overactive Bladder Treatment Market- Industry Landscape
10.1 Overview
10.2 Organic Developments
10.2.1 Overview
11. Company Profiles
11.1 Alembic Pharmaceuticals Limited
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Astellas Pharma Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 AbbVie Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Teva Pharmaceutical Industries Ltd
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Endo Pharmaceuticals Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co., Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Medtronic Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Pfizer Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
Table 1. UK: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 2. UK: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 3. UK: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 4. UK: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 5. Germany: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 7. Germany: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 8. Germany: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 9. France: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 10. France: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 11. France: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 12. France: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. Italy: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 14. Italy: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 15. Italy: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 16. Italy: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 17. Spain: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 18. Spain: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 19. Spain: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Europe: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Europe: Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Europe: Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (US$ Million)
Table 25. Organic Developments Done by Companies
Table 26. Glossary of Terms
Figure 1. Europe Overactive Bladder Treatment Market Segmentation
Figure 2. Europe Overactive Bladder Treatment Market Segmentation, By Country
Figure 3. Europe Overactive Bladder Treatment Market Overview
Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in Europe Overactive Bladder Treatment market
Figure 5. UK Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. Europe: PEST Analysis
Figure 8. Europe Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
Figure 9. Europe Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2019- 2028
Figure 10. Europe Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
Figure 11. Mirabegron: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Botox: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Neurostimulation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Transcutaneous Sacral Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Transcutaneous Tibial Nerve Stimulation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
Figure 16. Percutaneous Posterior Tibial Nerve: Europe Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
Figure 17. Others: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
Figure 18. Anticholinergics: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Solifenacin: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Oxybutynin: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Fesoterodine: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Darifenacin: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Tolterodine: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Trospium: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Other Anticholinergics: Europe Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Intravesical Instillation: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Europe Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
Figure 28. Idiopathic: Europe Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Neurogenic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 30. Europe: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (US$ Million)
Figure 31. Europe: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
Figure 32. UK: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Germany: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. France: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Italy: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Spain: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Rest of Europe: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US$ Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Alembic Pharmaceuticals Limited
- Astellas Pharma Inc
- Endo Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- Medtronic Plc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 153 |
| Published | January 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1111.05 Million |
| Forecasted Market Value ( USD | $ 1318.55 Million |
| Compound Annual Growth Rate | 2.9% |
| Regions Covered | Europe |
